High Dose Drug Device
Drugdevice inserted for 4 days
NCT Number: NCT01016691
Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 2
Miami, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
device inserted for 4 days
device inserted for 4 days
device inserted for 4 days
one drop in each eye on one day only
Time frame: Baseline to Day 1
Time frame: Baseline to Day 2
Time frame: Baseline to Day 3
Time frame: Baseline to Day 4
Time frame: Day 4 to Day 5
Vistakon Pharmaceuticals
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03891446
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT03850782
Eye Diseases, Glaucoma
Sun City, Arizona, United States
View Trial DetailsNCT04647214
Eye Diseases, Glaucoma
Culver City, California, United States
View Trial DetailsNCT04910100
Eye Diseases, Glaucoma
Newport Beach, California, United States
View Trial Details